header logo image


Page 733«..1020..732733734735..740750..»

Secukinumab has Early and Sustained Efficacy on Enthesitis in Patients with Psoriatic Arthritis – Pharmacy Times

January 10th, 2020 9:53 pm

Secukinumab has Early and Sustained Efficacy on Enthesitis in Patients with Psoriatic Arthritis

Enthesitis is inflammation of the entheses, the site where ligaments or tendons insert into the bones. Common locations for enthesitis include the bottom of the feet, the Achilles tendons, and the places where ligaments attach to the ribs, spine, and pelvis.2

Patients with enthesitis are known to have worse outcomes than patients without enthesitis. Using pooled data from the FUTURE 2 and 3 studies, a research team explored the use of secukinumab to limit enthesitis in patients with PsA.1

FUTURE was a phase 3 randomized, double-blind, placebo-controlled multicenter study that analyzed the 24- to 52-week efficacy, safety, and tolerability of subcutaneous secukinumab in prefilled syringes. Researchers used the Leeds Enthesitis Index (LEI) that consists of 6 sites: bilateral Achilles tendon insertions, medial femoral condyles, and lateral epicondyles of the humerus. Tenderness at each site is quantified by a number scale: 0 means nontender and 1 means tender.4

The post hoc analyses included the resolution of enthesis count (EC=0), median time to first resolution of enthesitis, and shift analysis of baseline EC (1, 2, or 3-6) to full resolution (FR) stable (similar or reduction of EC), or worse (EC > baseline).1

Sixty-five percent (466/712) of patients had baseline enthesitis. In the overall population, FR was achieved as early as week 16 in 65% (300 mg) and 56% (150 mg) versus 44% in the placebo group, with further improvements to 91% (300 mg) and 88% (150 mg) at week 104. The majority (89%) of patients without enthesitis at baseline maintained their status at week 104.3

In patients with EC of 1 or 2, shift analysis from baseline to week 24 showed that more patients achieved FR with secukinumab 300 mg and 150 mg versus placebo, whereas no difference between secukinumab and placebo was shown in patients with more severe symptoms with an EC of 3 to 6. Improvements in efficacy outcomes were similar in patients with or without enthesitis treated with secukinumab 300 mg.1

Secukinumab provided early and sustained resolution of enthesitis in patients with PsA over 2 years, the study authors noted.1 Secukinumab 300 mg provided higher resolution than 150 mg in patients with more severe baseline EC and showed similar overall efficacy in patients with or without enthesitis.

Reference

See the original post here:
Secukinumab has Early and Sustained Efficacy on Enthesitis in Patients with Psoriatic Arthritis - Pharmacy Times

Read More...

JIA Orofacial Pain Linked to Stress, Activity Limitations, Study Shows – Juvenile Arthritis News

January 10th, 2020 9:53 pm

People withjuvenile idiopathic arthritis (JIA) who experienceorofacial pain pain in the mouth, face, and jaw have more stress, limitations on daily activities, disease activity, and systemic inflammation than those who do not, a study reports.

The study, Orofacial pain in juvenile idiopathic arthritis is associated with stress as well as psychosocial and functional limitations, was published in the journal Pediatric Rheumatology.

The hallmarks of JIA are swelling of the joints, pain, and stiffness, typically in the knees, hands, or feet. JIA can affect other joints as well, such as those that connect the jaw to the head, which are known as the temporomandibular joints (TMJ).

Up to 96% of children with JIA develop TMJ arthritis, where stiffness, crepitus (joint popping), and restricted mouth opening are often reported.

Chronic or recurrent pain and disability in children and adolescents can limit their ability to function and grow properly. Many of these patients refrain from going to school and avoid engaging in social activities due to the psychosocial stress and pain associated with the disorder.

To investigate the relationship between psychosocial stress, along with inflammatory activity, and pain and function of the jaw, a group of researchers in Sweden studied 45 JIA patients ages 6 to 16. Sixteen children without JIA were also included as controls.

A clinical assessment, including both a physical and a psychosocial component, was conducted on all participants by one dentist.

Pain intensity and pain-related disability were assessed with the Graded Chronic Pain Scale. Limitations to jaw function was evaluated using the Jaw Functional Limitation Scale.

A four-item Patient Health Questionnairewas used to assess depression and anxiety symptoms. The Pain Catastrophizing Scale was applied to determine the degree of catastrophizing (believing pain is worse than it is), and the 10-item Perceived Stress Scale was used to evaluate stress.

The Childhood Health Assessment Questionnaire was used to assess ability to conduct daily life activities among children with JIA, while the body-drawing part of the McGill Pain Questionnaire was used to record pain locations.

Finally, the team used the Juvenile Arthritis Disease Activity Score,which includes an active joint count, a physician global assessment, a parent global evaluation, and the erythrocyte sedimentation rate (an indicator of systemic inflammation).

Results showed a strong association between experiencing orofacial pain and stress. Among patients scoring higher (worse) than normal in perceived stress, eight out of ten had self-reported orofacial pain.

Orofacial pain also significantly correlated with pain-related disability, depression, pain catastrophizing, and limitations in daily activities.

The team then compared clinical and psychosocial factors of JIA patients who experienced jaw pain with those who did not.

Orofacial pain was significantly associated with pain intensity, maximum mouth opening, and limitations on jaw functioning. JIA patients with orofacial pain also had higher disease activity and systemic inflammation than those without such pain.

In contrast, neither depression nor pain catastrophizing were linked to orofacial pain.

This study indicates that orofacial pain in patients with JIA is associated with stress, psychological distress, jaw dysfunction and loss of daily living activities, the researchers said.Pain intensity seems to be the major aspect related to these factors. In addition, increased disease activity with more joint involvement seems to be an important factor contributing to orofacial pain in JIA.

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where hes helping make medical science information more accessible for everyone.

Total Posts: 11

Jos is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.

Visit link:
JIA Orofacial Pain Linked to Stress, Activity Limitations, Study Shows - Juvenile Arthritis News

Read More...

Why I Relate to ‘Survivor’ as Someone With Rheumatoid Arthritis – Yahoo Lifestyle

January 10th, 2020 9:53 pm

I spent my summer watching Survivor. You know, the reality television show that shows people living in rugged, beautiful climates, taking part in challenges and voting each other off the island every few days. I was a fan when it started in 2000, but over the years, schedules and life turned my attention to other viewing pleasures.

Back then, I liked the beautiful settings and the intrigue among the cast members who were creating these intense relationships from living together in harsh circumstances and then back-stabbing those same people as part of the game. But what I really loved were the challenges. These usually took the form of giant obstacle courses, either on a sandy beach or in the ocean. Contestants swam, jumped, dug, wiggled and ran their way to winning rewards or immunity from being voted off. I liked to think about how I would do that and what skills I would bring to such fun.

Related: 10 'Hidden' Symptoms of Rheumatoid Arthritis We Don't Talk About

But this summer was different.

After years away from the show, this summer I found 34 seasons on Hulu and binged my way through season after season. I was able to do this because this summer a rheumatoid arthritis flare that included severe back pain and fatigue put me in bed with just a phone and a remote. I spent hours watching Survivor, drawn in by something internal and strong. At first, I wasnt sure what the lure was, but then it occurred to me.

I saw myself on that screen, except this time through the lens of my new reality.

When contestants would swim into the ocean, climb a ladder to retrieve a special key, then swim back, struggling to pull themselves on to a platform, I saw myself. I recognized that deep, unshakable fatigue, even though the genesis was different for them than for me.

When it rained for five days straight and their fire went out so they could only eat coconut in wet clothes, I recognized the despair on their faces from not knowing when this particular pain would end.

Related: 13 Things People Who Have to Give Themselves Shots Wish Others Understood

When a downcast contestant would dig deep and finish a challenge just when they needed the win, I found inspiration in my own battle for a win.

When their families showed up as a surprise reward, I wept from knowing how sustaining that unconditional love is and the hope it brings.

Yes, I saw myself in these Survivor contestants. No, I wasnt wearing a bathing suit on national TV or wrestling another person to try to win fishing gear, but I was in my own battle. It was a battle that included pain, despair, fatigue and hope. It was a battle that meant I had to will all my internal strength to be the victor. And as summer ended and my pain eased, I realized that I too, in my own reality, could call myself a Sole Survivor.

5 Tips for Success With Medical Cannabis

What Its Like When Doctors Blame You for Your Chronic Illness

8 Ways to Partner With Your Doctor and Take Charge of Your Healing

How I Took Walking for Granted

Read the original post:
Why I Relate to 'Survivor' as Someone With Rheumatoid Arthritis - Yahoo Lifestyle

Read More...

Doctors Missed Her RA Symptoms in Pregnancy. She Found a Way to Thrive Anyway – HealthCentral.com

January 10th, 2020 9:53 pm

Brooke Baker was sleeping soundly one night in 2005 when suddenly she woke up with new and excruciating pain in both shoulders. "I remember it so well, and I had no idea what was going on," recalls the Oklahoma native, now 39. "The pain was like someone was injuring me, and I couldn't go back to sleep for hours."

In the agonizing days to come, a perplexed and frightened Baker swapped out her mattress and her pillow and would prop herself up to try and alleviate the unrelenting stabbing sensations.

I just thought, Well, it must be one of those things, she says. But then that thing moved to her elbows, the next week to her wrists, and a week later, to her hands. I had never had any pain issues, and this all made me feel so debilitated. Having such painful arms and hands was especially unfair. Baker had been a full-time music minister at church for three years, playing the piano.

Realizing the continuing torment was anything but random, she went to see her OB/GYN. After all, she was eight weeks into a miracle pregnancy at the time (shed been told shed never be able to have children). The last thing she needed was unexplainable pain.

When I said: Something's wrong, during that office visit, both the nurse and the male doctor I saw told me I should be grateful to be pregnant and basically to suck it up, she says. Baker vowed to find a new OB/GYN, which she did four months into her pregnancy. At that point the pain was in every joint, from her neck to her toes.

This doctor was a little gentler, he did really listen, but he was also a poor communicator, Baker says. Because her symptoms were suspicious, the doctor did refer her to a local rheumatologist who ran some tests to confirm or rule out the possibility of rheumatoid arthritis (RA). That was the first mention that this disease could be the cause of her pain.

The rheumatologist later called me to report the results showed nothing, Baker says. Later, he also told me it definitely wasn't RA and that RA gets better when you're pregnant.

With her diagnosis still undetermined, the now-devastated and overwhelmed mother-to-be was in too much pain to work, so she quit and moved back in with her parents, because on top of all of this, her marriage had fallen apart.

I was on the couch for almost seven months, she says. The pain got better for about six weeks, between months seven and eight, says Baker. I finally felt better and hoped I was over it all.

It wasn't to be. The pain returned full force during her ninth and final month of pregnancy as she was also getting huge, she says. Almost sheepishly, she returned to her OB/GYN for pain relief. I didn't want anyone, including him, to think I was crazy.

That doctor told her: When you have the baby, you won't hurt anymore. Wrong: Her pain kept steadily increasing.

The calendar had flipped to 2006 now and the big day came to deliver. A c-section was complicated by my previous abdominal surgeries and resulted in a longer hospital stay and blood transfusions, Baker says. But my baby boy, Jackson, was healthy and I was thrilled!Still, her intense joint pain persisted. How would she manage being a single mother? Her doctor then told her: When you stop breastfeeding, you won't hurt anymore. But when she stopped after a year, her pain continued on.

I thought, If I just tough it out longer, I'll be OK, she says. I was pretty gullible, believing everything I was told.

Being a single mom is hard enoughbut fate would deal her another unlucky hand. Baker was worried: It seemed that Jackson, then 17 months old, was drinking constantly. Then one day he began stumbling, he couldnt see normally, and he'd been losing weight. She knew something was terribly wrong.

A doctor visit and blood tests showed his blood sugar was more than 750 mg/dL when he was diagnosed with type 1 diabetes. (Normal blood sugar for a person without diabetes ranges from between 70 and 100 mg/dL.) Frequent urination, thirst, fatigue, and weight loss are common symptoms of the disease.

He was too young to tell me what was wrong, how he was feeling, says Baker. His behavior changes and voice gave her clues as she tested his blood sugar regularly.

Baker was in nursing school by this time, still living with her parents and not working, except to play music part-time at a little, bitty job, she says.

In those first stressful weeks after his diagnosis, I'd stay up studying until 2 a.m., check my son, then sleep till 5 a.m. or 6 a.m. and then start it all over again, Baker says, knowing it was all worth it, even though then, it all felt almost unbearable.

I went through the roof at that time, Baker says, recalling seemingly insurmountable stress. Three weeks after her son's diagnosis, she finally saw her primary-care provider, where she wished she'd started, and tearfully confessed that she couldn't move her arms.

I couldn't even lift my baby. I'd have to scoop him, she says. I'd spend 30 minutes in the shower, in the warm water, to help get my arms moving in the morning, because they were 'locked' at a 90-degree angle.

The situation was terrifying. The baby relied on me for everythingme, the single mother trying to do everythingand I could barely take care of myself. I couldn't open a baby food jar, and didn't feel safe bathing him alone, Baker says. Thank goodness for my mother. But this was about survival, and I had to go on.

Her healthcare provider immediately did new blood tests for RA and he called Baker the same night to confirm positive results. "I was so glad to have an answer that I wasn't even devastated by that news," she says. The previously reported test resultsthe ones that ruled out RA while she was pregnantmust have been a mistake, she thinks now.

Her doctor quickly referred her to another rheumatologist who didn't just mumble and grunt at me, she says. He prescribed medication, and I started it in December 2007.

As for why Bakers OB/GYN had earlier ruled out RA because her symptoms continued during pregnancy, which, he said, was not the normit turns out he was half right and half wrong.

The latest research in UpToDate, an evidence-based clinical resource, says approximately 50% to 60% of pregnant women diagnosed with RA do have improvement in their symptoms, usually starting in the first trimester. And no, it's not possible to predict which patients will improve and which will flare.

Even more specifically, a review recently published in The Journal of Rheumatology reported that disease activity improved in 60% of patients with RA in pregnancy and flared in 46.7% postpartum. The Arthritis Foundation says that may be because of the hormone and immune system changes that protect an unborn child may also help RA.

The RA medication her doctor started her on was methotrexate, and it still stabilizes Baker's RA. It's a disease-modifying anti-rheumatic drug also known as a DMARD and it's considered a first-line treatment for RA. As the Johns Hopkins Arthritis Center shares, its benefits include that it works fairly quicklyin six to eight weeksit works well, is easy to use, and isn't expensive.

Bakers joints throbbed when she started taking it. She'd feel good for a few days, and then after the next week's injection, the pain would return. It took seven months before I started to feel normal, again, but a year later I was pretty much functional and able to play piano again! she says.

Baker has gone back and forth between methotrexate pills and now-weekly injections. She feels so much better now that she shudders to remember the two miserable years she spent with no pain medication except acetaminophen.

No one ever gave me any, she says. They just said: Everyone hurts when they're pregnant.

Jackson, Bakers now 13-year-old son, has clearly inherited his mother's indomitable, can-do attitude. His spirit is undefeatable, and he just bounces back with a resiliency that's amazing, Baker says of her son. His hasn't been an easy life and he makes it look so easy.

When Jackson doesn't feel well, he doesn't let it bother him. Instead he asks: "Can I go to school tomorrow? Baker patiently explains that he should rest and asks him to pace himself.

She homeschooled him until fifth grade and he thrived when he eventually attended school. Hes so motivated, just so driven, and wants to get into Harvard, she says. Hes also creative and talented and plays the lead in lots of school plays.

Getting to this point has meant thatmuch like his momJackson has had to overcome the awful moments that come with chronic illness. Baker recalls when, as a child, Jackson would say, I don't want to be diabetes, Mommy.

That was just heart-wrenching, Baker says. Now he's so calm, and he says to me: Diabetes isn't all that bad. There are more good things than bad things. That stumps me, and I just go blank, without a response.

He has said he doesn't quite understand it all, about why he hurts and can't get better, and why she hurts, too. Hes starting to assess when my hands and feet swell, and he says Im so sorry you have this rheumatism, she says.

Baker doesn't dwell on sorry, but stays active. She is part of the Diabetes Patient Advocacy Coalition that advocates for more affordable insulin. Shes been to Washington, D.C. three times in 2018 and 2019 to lobby her legislators to decrease the price of insulinand she intends to continue. As a partial result of the groups nationwide efforts, the Insulin Price Reduction Act was introduced July 22, 2019.

Baker isnt looking for a standing ovation, but she measures her lifes progress quietly every day, her eye firmly on the prizeand her goals.

With her pain controlled, and now her stress, Baker, who lives with her son, can focus on her accomplished life. She began that nursing degree in January 2008, around the time both she and her son were diagnosed with their diseases, and she finished in May 2010. Then in January 2019, she finished her masters degree in nursing and now works as a professor at a local university teaching the next generation of nurses. She will pursue her Ph.D. next, with the goal of becoming a university dean. Then there are more personal goals.

I want to be more active with my son when I can, Baker says. My body's getting physically stronger, and we're planning to do some runs together soon.

And theres travel. The pair plans to visit all 50 states. She's done 47, and Jackson has logged 10. Baker still plays music for therapy, not performing, but singing joyfully with her son in the car.

Shes relieved not to have to fight her body anymore. I'm trying to work with it instead of against it, she says. I dont accept it as: Boy, I love having this, but it's better than hating it all the time.

RA Reminds Her That Pain is Real, and Personal

Baker takes a whole-body approach to managing her RA. She consistently takes her medicationon timeand also likes to use essential oils for aromatherapy and for minor relief, applying them to her hands. To maintain her overall balance, she practices yoga, her favorite activity. She embraces deep breathing and calming apps on her phone, such as Calm and Headspace.

I do my part, and because I have a spiritual side, I leave the rest because I can't control it all, she says.

Baker remembers the time when doctors didnt hear her when she reached out for help with pain and she felt sheepish about pressing themnot so now. She encourages others with chronic illness to speak up for themselves. Youll experience a real difference between advocating and not, and if you dont find support in doctors you have, keep trying until someone really listens to you and works with you, she says.

It's made her a better nurse, especially when a patient shares about their pain. She learned in nursing school that pain is what the patient says it is. Baker knows this firsthand. Those months of gritting through intense pain during her pregnancy could have been shortened if only someone had really listened to her symptoms and pushed for treatment. Now Baker is doing the listening (and teaching) and her patients are lucky to have her.

See more helpful articles:

Let's Talk About Rheumatoid Arthritis

9 Conditions That Mimic RA

13 Supplements That Can Help Your RA

Read the original here:
Doctors Missed Her RA Symptoms in Pregnancy. She Found a Way to Thrive Anyway - HealthCentral.com

Read More...

Tai-Chi, Topical Capsaicin Among the New Treatment Recommendations for Osteoarthritis – Rheumatology Network

January 10th, 2020 9:53 pm

The American College of Rheumatology (ACR), in partnership with the Arthritis Foundation, has issued treatment guidelines for osteoarthritis of the hand, hip and knee. This is the first update since 2012.

New in this release is the inclusion of patients in the decision-making process, which the Arthritis Foundation described a "patient-centric guidelines."

Traditionally, the patient voice has been invoked, but not always present, as guidelines are developed, said Guy Eakin, senior vice president of scientific strategy for the Arthritis Foundation. Through our partnership we were able to marry the ACR rheumatology expertise with the Live Yes! patient community to pioneer a process assuring guidelines that treat patients reflect the unique perspectives of the patients who will receive them.

The guidelines, which will be published in February in an ACR journal, emphasizes the adoption of basic therapeutic treatments which were strongly recommended. These include: weight loss; self-management programs to build fitness skills and exercise goalsetting. Previously consider conditions recommendations, the following were upgraded to strong recommendations: mind-body approaches such as tai-chi; topical NSAIDs for knee and hand osteoarthritis; oral NSAIDs and intra-articular steroids for knee and hip osteoarthritis.

Other recommendations include:

REFERENCE: Sharon L. Kolasinski, Tuhina Neogi, Marc C. Hochberg, et al. "2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee." January 2020. Arthritis Care and Research. DOI:10.1002/acr.24131

See the original post here:
Tai-Chi, Topical Capsaicin Among the New Treatment Recommendations for Osteoarthritis - Rheumatology Network

Read More...

Lyme disease: Justin Bieber’s tick-bite illness can cause joint pain, heart problems, and depression – The Conversation UK

January 10th, 2020 9:53 pm

Justin Bieber recently announced that for the last couple of years hes been battling Lyme disease. Lyme disease, which is caused by the bacterium Borrelia burgdorferi, can be transmitted to humans if theyre bitten by an infected tick. In fact, its one of the most common tick-borne diseases in the west. An estimated 300,000 people in the US are diagnosed with it every year. The disease causes a range of debilitating symptoms, which can include severe headaches, neck stiffness, arthritis, joint pain and rashes. These symptoms can last for months or even years.

After being bitten, most people develop a red, circular rash, which may slowly expand beyond the bite site. Only around 20-30% of people will develop the characteristic bullseye rash. Without prompt treatment, the bacteria will spread from the bite site to tissues and organs, leading to additional skin lesions and a range of debilitating and persisting symptoms, such as pain, fatigue, memory problems and arthritis.

Perhaps alarmingly, instances of Lyme disease have actually become more common. In England and Wales the number of cases has increased from 1,134 in 2016 to 1,579 cases in 2017. The increase might be explained by a number of factors, including global warming (ticks survive better in warm weather) and increasing wildlife populations. Better diagnostic tools and increased awareness might also explain the surge in Lyme disease diagnoses.

Lyme disease can have a considerable impact on many aspects of the lives of the patient and their families. In severe cases, patients can be bedridden or wheelchair-bound for years without knowing if they will recover. Affected people may also experience anxiety, depression or distress, which can reduce their quality of life and deeply affect their mental wellbeing potentially even resulting in thoughts about suicide.

In most cases, a person will be diagnosed with Lyme disease based on whether they have the illnesss characteristic skin lesions especially if they live in an area where ticks carry Lyme disease. Although blood tests can also be used, these tests might only be 30-40% effective at detecting the disease in its early stages. But if the disease has already spread throughout a persons body, these results can be 100% accurate.

Giving a clear diagnosis of Lyme disease can be difficult, however. This is because many patients have a range of non-specific clinical symptoms, such as fatigue, malaise, headache, fever, sweats, joint aches and brain fog. Disease test results might also be similarly difficult to interpret, especially in patients that do not have the hallmark skin rash of Lyme disease and lack a recent history of exposure to tick bites. This makes dealing with the lingering infection difficult, especially where tests give inconclusive results.

In fact, people suffering from Lyme disease can also suffer from other tick-borne illnesses, such as babesiosis, which can be transmitted with Borrelia burgdorferi during the tick bite. This makes treatment even more complicated. As well, there is still some controversy about the right length of effective antibiotic therapy to treat patients with persistent, chronic Lyme disease. As a result, patients can, and usually do, feel helpless amid conflicting medical advice in fighting the disease.

Lyme disease is primarily treated with antibiotics. Early skin lesions and symptoms can be treated with the oral antibiotic doxycycline, usually for anywhere between ten to 21 days. Patients with neurological symptoms (including meningitis and encephalitis), heart inflammation or arthritis, are usually treated with a two-week course of intravenous ceftriaxone therapy. In most cases, timely diagnosis and prompt antibiotic treatment can improve symptoms.

But a misdiagnosis or late diagnosis can result in long-term illness, excessive use of antibiotic therapy, and expensive healthcare costs. Ignorance of the complex nature of this illness, especially the associated mental health issues, will further delay recovery. Dealing with these psychosocial problems regardless of whether they were triggered by Lyme bacteria or not can complement treatment and promote a quicker recovery.

Continued research and awareness about Lyme disease will be important for improving treatment and diagnosis. Developing more reliable diagnostic tests, identifying which patients are most likely to benefit from which antibiotic treatments, and taking measures to control tick populations will all be important for reducing instances of this disease in the future.

People can cut down on their risk of contracting Lyme disease by covering their skin in tall, grassy, wooded areas where disease-carrying ticks thrive. If you think youve been bitten by a tick, contact a doctor or health professional.

Excerpt from:
Lyme disease: Justin Bieber's tick-bite illness can cause joint pain, heart problems, and depression - The Conversation UK

Read More...

Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis – Open Access Government

January 10th, 2020 9:53 pm

Endocannabinoids, as well as several phytocannabinoids, have been shown to influence immune functions, regulating inflammation, autoimmunity, antitumourigenesis, antipathogenic responses and other processes.1 Numerous in vitro and in vivo studies have examined the therapeutic potential of cannabinoid signalling in inflammation-associated diseases (e.g. psoriasis) and attempted to dissect the complex immunological effects of cannabinoids.

Psoriasis is a chronic inflammatory disease of the skin, characterised by excessive proliferation of keratinocytes that results in the formation of thickened scaly plaques, itching and inflammatory changes of the epidermis and dermis.2 The underlying pathophysiology involves activation of classes of T-cells and their interaction with dendritic cells and other cells of the innate immune system, including neutrophils and keratinocytes.3

The following pre-clinical studies support the use of cannabinoids in the treatment of psoriasis:

A 2003 study in Journal of Clinical Investigation demonstrated that the cannabinoid receptors CB1 and CB2 are present in human skin cells, including keratinocytes;4

A 2003 study showed that anandamide, an endogenous CB receptor ligand, inhibits epidermal keratinocyte differentiation (abnormal keratinocyte differentiation is a hallmark of psoriasis);5

In 2004, a study in the Journal of Neuroimmunology used an in vivo mouse model to show that THC can shift the development of the predominantly pro-inflammatory T helper 1 (Th1) cell to the more anti-inflammatory (Th2) cell type profile;6

A 2007 study, published in the Journal of Dermatological Science, demonstrated that a range of cannabinoids inhibit keratinocyte proliferation in hyperproliferating human keratinocyte cell lines.7 The cannabinoids inhibited keratinocyte proliferation in a concentration-dependent manner. The activity of CBN (not significantly active at CB1/CB2 receptors) indicates more than one mechanism of action;

In 2011, a study using human cultured keratinocytes and a skin organotypic culture model, provided evidence that anandamide markedly suppresses keratinocyte proliferation and induces cell death, both in vitro and in situ. The cellular actions were mediated by CB1 and transient receptor potential vanilloid-1 (TRPV1). The cellular effects of anandamide are most probably mediated by Ca2+ influx and intracellular accumulation via the non-selective, highly Ca2+-permeable ion channel TRPV1. The study was published in the Journal of Investigative Dermatology;8

A 2016 study, published in the Annals of Dermatology, investigated the effect of CB1 agonists on mast cell activation. The authors found that CB1 agonists inhibited the release of inflammatory mediators and markedly and dose-dependently suppressed cell proliferation.9

RA is one of the most prevalent autoimmune diseases and one of the main causes of disability globally, causing pain, joint malformation and joint destruction.10 Preliminary evidence suggests that cannabinoids have a role in the future treatment of RA.

In one study,11 protein and mRNA expression of endocannabinoids, AEA and 2-AG, and cannabinoid receptors, CB1 and CB2, were found in synovial tissue obtained from 13 patients diagnosed with RA and undergoing arthroplasty whilst synovial tissue obtained from healthy volunteers was negative for the same endocannabinoids. Another study of synovial tissue from patients with RA12 found that of inflammatory cytokines, IL-6 and IL-8, which are stimulated by synovial cells, were attenuated by low concentrations of the synthetic cannabinoid WIN 55,212-2.

Furthermore, three different research groups achieved improvement in mice with collagen-induced arthritis (CIA), following treatment with various cannabinoids;13 The use of cannabinoids for the treatment of pain associated with RA has been assessed in only one 2006 clinical trial, where 58 patients with RA were allocated either nabiximols or a placebo.14 Compared with placebo, patients treated with nabiximols exhibited decreased pain along with improved sleep quality.15

1 Olh, A., et al. (2017) Targeting Cannabinoid Signalling in the Immune System: High-ly Exciting Questions, Possibilities, and Challenges. Front Immunol 8:1487.2 Habif, TP. (2016) Psoriasis and other papulosquamous diseases. Clinical Dermatology. 6th ed. Philadelphia, PA: Elsevier 263-328.3 van de Kerkhof, PCM and Nestl, FO (2018) Dermatology. 4th Edition, By Bolognia, JL., et al. 8, Psoriasis 138-160.4 Casanova, ML., et al. (2003) Inhibition of skin tumour growth and angiogenesis in-vivo by activation of cannabinoid receptors. J Clin Invest 111:43-50.5 Maccarrone, M., et al. (2003) The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278:33896-33903.6 Klein, TW., et al. (2004) Cannabinoid receptors and T helper cells. J Neuroimmunol 147:91-94.7 Wilkinson, JD., et al. (2007) Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatolog Sci 45:87-92.8 Tth, BI., et al. (2011) Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. J Invest Dermatol 5:1095-104.9 Nam, G., et al. (2016) Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model. Ann Dermatol 28(1):22-9.10 Shapira, Y., et al. (2010) Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 6:468476.11 Richardson, D., et al. (2008) Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 10(2):R43.12 Lowin, T., et al. (2016) The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets. J Inflamm 13:15.13 Malfait, AM., et al. (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97:95619566; Fukuda, S., et al. (2014) Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet Disord 15:275; Gui, H., et al. (2015) Activation of cannabinoid receptor 2 attenuates synovitis and joint destruction in collagen-induced arthritis. Immunobiology 220:817822.14 Blake, DR., et al. (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45:5052.15 Blake, DR., et al. (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45:5052.

*Please note: This is a commercial profile

Editor's Recommended Articles

Here is the original post:
Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis - Open Access Government

Read More...

Chilled to the bone the link between cold weather and joint pain – StarNewsOnline.com

January 10th, 2020 9:53 pm

By Max Shenin, DO

WednesdayJan8,2020at6:01AM

Editors Note: This article is made possible through a sponsored content partnership with New Hanover Regional Medical Center.

Chilled to the bone. Many of us have used this expression after spending some time outdoors in the cold weather. But it leads to perhaps one of the most common questions posed to all rheumatologists: Does the weather have any impact on our bones or joints? Many people are convinced that they are able to predict the weather based on increase in joint or back pain. A commonly quoted study conducted more than 10 years ago seemed to support this notion by showing that every 10-degree drop in temperature as well as a drop in barometric pressure can increase joint pain.

The Arthritis Foundation even provides an arthritis index on its website that is based on local temperature and barometric pressure that anyone can use if they chose. So mystery solved, right?

Not so fast. Like so many things in medicine, our knowledge is always evolving. One of the more recent and largest studies to date found absolutely no connection between changes in weather and joint pain. This conclusion was based on very comprehensive data collected from over 10 million doctor visits. And then there was another recent Dutch study that showed an increase in barometric pressure and humidity correlated well to increased joint pain, which directly contradicted the previous notion that the drop in barometric pressures was the culprit for your achy bones.

Digesting all of these conflicting findings can be a challenge for clinicians and patients alike. The reality is that the verdict is likely still out on this complex issue and there is more data to come. Until we get some more clarity, my recommendation is to go with whatever your body tells you. After all, no science can compete with personal experience that tells you that the ache you feel in your knees probably means that you should get your umbrella ready.

Dr. Max Shenin is a board-certified and fellowship trained rheumatologist with NHRMC Physician Group Rheumatology. To make an appointment, call 910.662.7550.

More here:
Chilled to the bone the link between cold weather and joint pain - StarNewsOnline.com

Read More...

CBD Technology and How CBD Patches Are Helping People – HealthTechZone

January 10th, 2020 9:53 pm

Thanks to the advancement in technology, it seems like CBD is making its way into everything nowadays. The list of CBD-infused products includes intimate gels, sparkling water, chocolate, gummies, shampoo, skin creams, coffee, and so much more. One of the latest addition to the list is CBD patches.

As you probably already know, patches have been existing for many years already and are famous for effectively delivering healthy ingredients into the bloodstream. Today, its now getting utilized as a vehicle for CBD to get into your body and help you enjoy the benefits of the chemical.

The Technology Behind How CBD Patches Are Created

The technology used in creating CBD patches has already been around for decades, despite the product being relatively new in the market. The technological concept is much similar to birth control or nicotine patches, added with a couple of twists to ensure that the patch can deliver CBD to the bloodstream effectively.

CBD patches contain a dose of Cannabidiol molecules, infused in an isolated oil, gel, or solution. They also have carriers and permeation enhancers, and because your skin has a low CBD concentration, the high concentration of the patch moves the Cannabinoid into your body.

CBD patches and their transdermal application continue to become famous as an alternative way to reap all the benefits that CBD supplements bring to the table. Many people also view it as a way to receive a prolonged treatment dosage while being discreet.

Like any other CBD-infused products available in the market today, CBD patches cant get you high since Cannabidiol functions differently than THC, the psychoactive element of Cannabis plants. Accurate, useful, and comfortable, CBD patches are as simple as they sound, even if the technological process they undertake is a bit complicated.

This post will help you take a closer look at CBD patches, how these products work, and how they can help people.

Whats A CDB Patch And How Does The Product Work?

If you want to picture out what CBD patches look like, you only have to imagine large band-aids since theyre very closely similar in appearance. Also, like a large band-aid, you can peel and stick a CBD patch to any location in your body. The only difference is that the CBD patches are pieces of plastic infused with Cannabidiol.

Unlike the typical CBD oils, the patches arent wet. Theyre dry so they can stick to your skin. Most users place them on venous parts of the body, including their arms, ankles, and wrists. They do this since those areas have the potential for a higher absorption rate of CBD into the bloodstream.

Cannabidiol patches function by following a complex chemical reaction with the users body. Your body heat will activate the pieces and causes them to release CBD molecules and other ingredients that they contain. Please take note that in addition to Cannabidiol, some patches may contain caffeine, melatonin, THC, and more. Once these molecules get absorbed through the skin, they make their way into the bloodstream, where the body can start processing the compounds. After that, youll then begin to experience the benefits of CBD.

Benefits of CBD Patches

One of the essential benefits of CBD patches is the efficient delivery of Cannabinoid to the body. However, there are other equally important benefits, as well.

Here are some benefits of CBD patches:

1. Better Compound Absorption - Whats the reason behind CBD patches better absorption? It starts with the fact that your lungs and stomach are excellent at preventing any chemical from entering your bloodstream, which is how other CBD products, such as vape and gummies, enter. While its great that such a defense mechanism is possible to protect your body when youve inhaled or ingested something harmful, it also means that anything beneficial that youve consumed may reach your cells with limited effects.

By using CBD patches, you can bypass the filtering organs of your body, so more of the compound makes it into the bloodstream. It results in less CBD needed for you to feel and experience the benefits of the chemical.

2. Pain Management - CBD patches, like other CBD-infused products, have shown to alleviate ailments-related pains in the body, including lower back pains, spinal cord injury, arthritis, cancer, multiple sclerosis, muscle spasms, chemotherapy, and depression.

You can use CBD patches to manage both acute and chronic pains. Like band-aids, youll have to apply the patch to the site or area where you feel pain, allowing the supplement to get delivered immediately or over a short period.

Some CBD patches can also last for three days through nanotechnology in the reservoir patch, so its best to weigh your options based on your needs.

3. Arthritis - One of the leading causes of disability in the USA is arthritis. More than fifty-four million adults in the country have arthritis, which is more common in women than men. One type of arthritis, osteoarthritis, affects thirty-one million in the country by causing joints inflammation.

Several studies have pointed out the effectiveness of transdermal doses of CBD to reduce pain and other symptoms related to arthritis.

Final Thoughts

Many CBD users prefer transdermal delivery because it can bypass the stomach, liver, and lungs entirely - the traditional organs that break down or filter the Cannabinoid. So, such a method of taking Cannabidiol can give you at least fifty percent up to one hundred percent of the value of the supplement.

Kyle Tresch

Kyle Tresch is a pharmaceutical scientist who researches the efficacy of new drugs and medicines. Kyles responsibilities include discovering new compounds that can treat certain illnesses, development of these compounds to assess its safety and efficacy among human beings, and the manufacture of these compounds into drugs for public consumption.

Kyle shares his expertise by contributing articles to various platforms online.

Continue reading here:
CBD Technology and How CBD Patches Are Helping People - HealthTechZone

Read More...

Upcoming events Pfizer’s abrocitinib and Myovant’s relugolix – Vantage

January 10th, 2020 9:53 pm

Welcome to your weekly roundup of approaching clinical readouts.Pfizers Jak 1 inhibitor abrocitinibwill need to prove itself against the dermatitis stalwart Dupixent in the phase III Jade-Compare trial, data from which aredue shortly. It is already known that abrocitinib works in atopic dermatitis, sinceit met key endpoints in two phase III trials. But the safety profile will need to beclosely analysed; Jak inhibitors have had to contend with serious toxicities when used in rheumatoid arthritis.

Abrocitinib is said to be selective for Jak 1, which investigators believe reduces the risk of class-related adverse events such as infections and thromboembolic and other cardiovascular events.

In abrocitinibs previous atopic dermatitis studies,Jade Mono-1 and 2, the rate of serious adverse events was 2-3% in treated patients, anddiscontinuations were in the 4-6% range, higher than the 2% previously seen with Dupixent. There were no thromboembolic events with Pfizers Jak, but there seem to be tolerability issues judging by the 10-20% rate of nausea and headache. In Dupixent studies the most frequent adverse eventswere injection site reactions and conjunctivitis.

In terms of efficacy the higher dose of abrocitinib showed comparable results to Dupixent in its pivotal trials. In the latest study, Jade-Compare, abrocitinib is pitted directly against Dupixent in adults on topical background therapy. Again 100mg and 200mg daily doses of abrocitinib are being tested, and the co-primary endpoints are investigators global assessmentand EASI-75 score at 12 weeks.

On Pfizers third-quarter call management specifically pointed to a secondary endpoint, pruritus reduction, where the company expects abrocitinib to outperform, as it inhibits the interleukin-31 that is a major itch mediator, which is not covered by Dupixent.

Displacing Dupixent will be tough given physicians' experience and the potential for a black-box warningfor abrocitinib, in common with other Jaks. OnPfizers side will be convenience: abrocitinib is oral and Dupixentsubcutaneous.

In terms of Jak competition Lillys Olumiant and Abbvies Rinvoq are in phase III trials in atopic dermatitis and approved,with black box warnings, in rheumatoid arthritis. Meanwhile, Dermira has just been bought by Lilly (Lilly jumps the gun with Dermira deal, 10 Jan 2020).

Myovant looks for Spirit guidance

For Myovant Sciences phase III endometriosis data due by the end ofthe second quarter will not just be about scoring a clinical win with its GnRH inhibitor relugolix; they will alsohopefully showsome benefit over the approved market leader, Abbvies Orilissa.

Relugolix has previously disappointed relative to expectations in cross-trial comparisons with Orilissa in uterine fibroids. And on its current development trajectory, even if the Spirit 1 and Spirit 2 trials are successful, the project will hit the market two and a half years after Orilissa. Strong data will be essential if Myovant is to stand any chance of taking market share from the pharma giant.

Relugolix and Orilissa both work by blocking the gonadotrophin hormone and reducing the pain associated with endometriosis, a disorder where tissues that usually line the wall of the uterus grow outside of the womb.

However, where Orilissa is used asa monotherapy, the Spirit trials are testing relugolix in combination withan oestrogen"add-back therapy". One of the biggest side effects of GnRH antagonists isbone loss, whichcan limit the duration of treatment. Add-back therapy can thus extend the treatment window for what is a chronic disease.

Myovant supporters have highlighted this as an advantage over Orilissa, alongside relugolixs dosing convenience. But Abbvie could hobble this advantage with results from a 681-patienttrialcomparing Orlissa monotherapy against a combination with hormoneadd-back. If thistrial is positive Leerink analysts say alabel extension for Orilissa could follow in the third quarter, six months beforerelugolixs forecast endometriosis approval.

With so much stacked up against Myovant it is not surprising that 2024 sales forecasts for relugolix in endometriosis are only $278m, compared with $843m for Orilissa, according to EvaluatePharma. The Spirit data will have tosurprise for Myovantto avoidbeing an also-ran in the indication.

Originally posted here:
Upcoming events Pfizer's abrocitinib and Myovant's relugolix - Vantage

Read More...

Webinar: Feed the Future Biotechnology Potato Partnership: Durable late blight resistance to South East Asia – Potato News Today

January 10th, 2020 9:51 pm

The World Potato Congress (WPC) is pleased to be offering thefirst webinar in its 2020series featuring Dr. David Douches on January 24, 2020 at 09:00 AM Eastern Standard Time (USA and Canada).

Abstract:The Feed the Future Biotechnology Potato Partnership (BPP) is a five-year, multi-institution cooperative agreement between MSU, USAID, Simplot Company and other global institutions to develop and bring to market improved potato products to low-income farmers in South East Asian countries.

BPP offers biotech potato products with broad-spectrum resistance to late blight (Phytophthorainfestans), the most devastating potato disease in the world, and highly endemic throughout Bangladesh and Indonesia. BPP provides strategic human and institutional capacity building and support (research, development and outreach) to in-country partners in Bangladesh (BARI) and Indonesia (ICABIOGRAD) to support access to, technology transfer, and sustainable use of biotech potato technologies.

The project also monitors and evaluates environmental impact, gender balance contribution and socio-economic impact of these biotechnologies. BPP and partner institutions will steward biotech potato products for distribution to low-income farmers and eventual commercialization. All of these activities support and align with USAIDs goal of increasing food security and resilience.

Dr. David S. Douches, with over 36 years of experience inpotato breeding and genetics, has an active potato breeding program directedtoward the development of improved cultivars in Michigan for 30 years.

Thefocus of the program is to develop new cultivars for Michigans potato industryby integrating new genetic engineering techniques with conventional breedingefforts.Key traits targeted forimprovement include Colorado potato beetle resistance, disease resistance to scab, lateblight and PVY, as well as chip processing from long-term storage.

Dr. Douches is the principle scientist of the Michigan State Universitypotato breeding and genetics program and Director of the USAID-fundedFeed the Future Biotechnology Potato Project for Indonesia and Bangladesh.

The host for the WPC webinar series will be WPC Director, Dr. Nora Olsen (norao@uidaho.edu).

Webinar RegistrationInterested participants will be able to interact with the presenterof the webinar. When: January 24, 2020 at 09:00 AM Eastern Standard Time (USA and Canada)

Register in advance for this webinar:https://zoom.us/webinar/register/WN_Svl0vOiUQyKZqtjfYCzqpgFollowing your registration, you will receive a confirmation email containing information about how to join the webinar.

All webinars are recorded and can be viewed via the World Potato Congresswebsite at http://www.potatocongress.org.

In case you missed any of WPCs 2019webinars listed below, they can be viewed on our website at http://www.potatocongress.org :

1.World Potato Congress Inc. Premier Global Networking OrganizationPresenter: WPC President, Romain Cools, Belgium

2.Geographic Constraints in Potato Breeding: Role of Day Length, Temperature and Light Intensity in Selecting for AdaptationPresenter: Dr. Peter VanderZaag, Sunrise Potato Storage Ltd., Canada

3.Best Management Practices for Seed Potato Handling from Storage to PlantingPresenter: Dr. Gary Secor, Professor in the Department of Plant Pathology, North Dakota State University, USA

4.World Potato Output and TradePresenter: Cedric Porter, Editor, Brexit Food & Farming and co-editor of World Potato Markets, UK

5.Why You Should Plant Certified Seed PotatoesPresenter: Dr. Nina Zidack, Director of Seed Potato Certification, Montana State University, USA

6. Illustration of Regional Potato Promotion:Flanders (Belgium)Presenter:Kris Michiels, Marketing Adviser, VLAM, Belgium

WPC looks forward to interacting with you during this initiative. We welcome all your feedback via email:info@potatocongress.org.

Like Loading...

Categories: Across Regions, All latest News, Breeding, Events, News January 2020, North America, Pests and Diseases, Pressreleases, Production/Agronomy, Research, Studies/Reports, Varieties

Read the rest here:
Webinar: Feed the Future Biotechnology Potato Partnership: Durable late blight resistance to South East Asia - Potato News Today

Read More...

40 Securities Added to Nasdaq Biotechnology Index – Nasdaq

January 10th, 2020 9:51 pm

Nasdaq recently announced the results of the annual re-ranking of the Nasdaq Biotechnology Index (NBI). The re-ranking was effective prior to market open on Monday, December 23, 2019. There are now 217 companies in the index, including 40 new additions. You can view the full list of securitieshere.

Along with this performance was a substantial increase in assets under management (AUM) for IBB the largest corresponding ETF that tracks the Nasdaq Biotechnology Index globally. In fact, the AUM as of December 31, 2019 was approximately $8B.

Since its inception, the NBI has shown impressive performance over the years. The market capitalization weighted index focuses specifically on the biopharmaceutical industry allowing Nasdaq-listed companies to gain exposure to passive investors.

Nasdaq continues to be the leader in biotechnology listings, including initial public offerings in the biotechnology and pharmaceutical arena such as Genmab, Bridge Bio and Gossamer Bio, Inc. In 2019, Nasdaq had a 100% BioPharma IPO win rate as we welcomed 55 BioPharma IPOs raising approximately $5.6 billion in IPO proceeds.

If you have any questions, including how to leverage inclusion in the index, please do not hesitate to contact me at Jordan.Saxe@nasdaq.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more:
40 Securities Added to Nasdaq Biotechnology Index - Nasdaq

Read More...

Alderaan Biotechnology raises 18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi – BioSpace

January 10th, 2020 9:51 pm

Paris, France, January 9, 2020 Alderaan Biotechnology, a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer, announces today the successful completion of a Series A funding of 18.5M ($20.7M) from investors Advent France Biotechnology (AFB) and Medicxi. This follows a seed funding round of 1.5M ($1.7M) in 2017, led by AFB.Founded by Pr Armand Bensussan, head of the Skin Research Centre, Saint Louis Hospital, Paris, and Pr Daniel Olive, head of the Immunity and Cancer team at Institut Paoli Calmette, Marseille, Alderaan Biotechnology focusses on developing technologies to deplete regulatory T (Treg) cells in cancer and to boost Natural Killer (NK) cell cytotoxic activity in cancer, both emerging as new immunotherapy modalities.This funding round will support the finalization of preclinical development to reach Phase I clinical stage, with the companys Treg depleting CD25-specific antibodies, by 2022. In parallel, the financing will also help validate thein vivotherapeutic potential of the NK asset related to the activating NK cell receptor CD160-TM (Alderaans second program).Both Medicxi and AFB, represented by Michle Ollier and Matthieu Coutet respectively, will co-lead the new investment as board directors.I am very pleased to welcome Medicxi to the company; its capital investment signals an exciting stage for Alderaan, said Arnaud Foussat, CEO of Alderaan Biotechnology. Modulating regulatory T-cells in cancer has a great therapeutic potential in oncology it could be a game changer. Our NK asset is earlier stage, but there is already a strong and encouraging interest from the pharmaceutical industry in the field.We have been working alongside Alderaan since day one and we are thrilled to be part of this next stage of development, said Matthieu Coutet, managing partner at Advent France Biotechnology. Alderaans area of focus is drawing attention from big names in the industry and the company has a solid scientific team to support its rationale.Alderaan perfectly fits with our aim, which is to invest in start-ups that have already reached scientific maturation and proof-of-concept, said Michle Ollier, partner at Medicxi. The companys technologies are very attractive to the pharmaceutical industry and could become key additional therapeutic tools for patients and health professionals.Advisors to AlderaanLegal: Mac DermottFinancial: DeloitteAdvisors to MedixciLegal: Jones DayAbout Advent France BiotechnologyAdvent France Biotechnology is an AMF regulated firm created in 2016. The team, managed by Alain Huriez and Matthieu Coutet, includes professionals with extensive scientific, medical and operational experience, as well as a long-standing track record of entrepreneurial and investment successes across Europe. AFB invests in a range of sectors within the life sciences, specifically in drug discovery and new medical technologies.www.adventFB.comAbout MedicxiMedicxi is a European venture capital firm with the mission to create and invest in companies along the full drug development continuum. Medicxi was established by the former Index Ventures life sciences team, which has been active for over 20 years, and invests in both early and late-stage assets with a product vision that can fulfil a clear unmet need.GSK, Johnson & Johnson Innovation JJDC, Inc.,Novartis and Verily (an Alphabet company) have invested in Medicxi funds.www.medicxi.comAbout Alderaan BiotechnologyAlderaan Biotechnology is a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer with technologies aiming at Treg depletion and NK cell modulation. Founded in 2017 and headquartered in Paris, Alderaan works with world-class teams in the field of immunomodulation and NK cell receptors. The company raised 1.5M ($1.7M) in 2017 from co-founder Advent France Biotechnology (AFB) and 18.5M ($20.7M) in 2019 from AFB and Medicxi.www.linkedin.com/company/alderaan-biotechnology/about/

The rest is here:
Alderaan Biotechnology raises 18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi - BioSpace

Read More...

Novadiscovery takes off with 5 Series A financing – European Biotechnology

January 10th, 2020 9:51 pm

In silico clinical trials pioneer Novadiscovery SA has raised 5m in a series A financing led by Swiss Debiopharm Innovation Fund.

French in silico clinical trial specialist Novadiscovery said it will use the 5m tranche of a 7m Series A funding round with Debiopharm Innovation Fund SA to scale its in silico clinical trial simulation platform Jink from a consulting to software as a service (SaaS) model, which is compliant with FDA priorities and requirements. Novadiscovery pioneers the use of in silicoclinical trials prior to human drug testing to predict drug efficacy and optimize clinical trail design. Several hundred disease and disease subtype-specific parameters are combined in the company's in silico models that mimic the physiology and co-morbidities of virtual patients.

Knowledge-based in silico modelling of clinical trials holds the potential to predict outcomes and optimise the design of clinical trials with the aim to reduce research & development (R&D) costs and time-to-market of novel drugs. Most recently, Novadiscovery accurately modelled the Phase I outcomes of the FXR agonist EYP001 in healthy and subjects infected with the hepatitis B virus (HBX) in a Phase I study. Furthermore, Jink was used to predict Phase II outcomes of a combination of EYP001 with standard therapy.

The Computational Model integrates 300+ biological variables and 600+ parameters. With seven mechanistic submodels (including the effect of FXR agonist on HBV replication, HBV excretion, bile acid physiology and EYP001, ETV, and pegylated interferon drug models), the model has been used to predict quantitative efficacy of treatments on disease-related endpoints (eg. plasma HBV DNA and HBsAg concentrations) in a virtual population. All the submodels are ultimately combined into a multi-scale Computational Model simulating the dynamics of biological entities at the molecular, cellular and organ levels.

We have seen the significant positive impact our in silico trials platform can have on reducing R&D costs and compressing time-to-market for new drugs and in drug repositioning, stressed Franois-Henri Boissel, CEO and Co-Founder of Nova. This funding allows us to accelerate the development of our platform in a SaaS model that will make it available to a growing number of clients and project, notably in the US. We intend to complete the 7m Series A in 2020.

Reducing R&D costs and time-to-market has become a key strategic objective for healthcare companies and payors. The in silico trial market is evaluated to grow to $2,88bn in annual revenue by 2022, when it will still represent only a small fraction of $165bn annual drug R&D spent.

Reducing number of real patients involved in clinical trials is also a main issue, for both the industry and the regulators. Because they are not so many considering the number of drugs to be evaluated, and their participation in a clinical trial must be as ethical as possible. Novas unique hybrid approach to running in silico clinical trials presents several benefits, one of which being that it can operate in data-poor environments, which is the biggest hurdle more conventional artificial intelligence (AI)-based approaches are facing.

View original post here:
Novadiscovery takes off with 5 Series A financing - European Biotechnology

Read More...

Former Tomorrows World presenter set to address biotechnology event – The Scotsman

January 10th, 2020 9:51 pm

Published: 16:50 Updated: 17:04 Monday 06 January 2020

A renowned scientist and former Tomorrows World presenter has been announced as one of the keynote speakers at the Industrial Biotechnology Innovation Centre (IBioIC) annual conference next month.

Vivienne Parry will address the event, which is now in its sixth year and expected to attract more than 450 delegates including IB business leaders, policy-makers, investors and innovators and technical experts from around the world. They will congregate in Glasgow on 5 and 6 February, and will see innovative companies exhibiting their smart solutions to a global audience.

Parry, a scientist by training, is the head of engagement at Genomics England and a UK Research and Innovation board member and has extensive writing and broadcasting experience that has inspired a generation of scientists.

She said industrial biotechnology (IB) start-ups need to get out and tell people what they are doing, quickly showing the solution to a problem scientists can sometimes struggle to communicate to policy-makers and the public the significance of what they are doing to save the planet.

READ MORE: Comment: Ever heard of industrial biotechnology? Our future may depend on itREAD MORE: Plans to boost Scotlands bio-revolution secure seed fundingKeep it simple and show the real value in your product and the positive impact it can make to everyday life and the environment. When I listen to someone presenting their concepts, I want them to excite me about the potential of their product in a way that is not hyped, but is really clear.

Mark Bustard, commercial director at IBioIC, said a change in mindset is needed if startups are to capitalise on their innovations. Companies like ScotBio, Cellucomp and Celtic Renewables are all fantastic examples of award-winning organisations who are driving science to generate and make products.

Link:
Former Tomorrows World presenter set to address biotechnology event - The Scotsman

Read More...

Debut Biotechnology Closes $2.6M Seed Round to Bring Continuous Biomanufacturing of High-Value Molecules to Pharma – PR Web

January 10th, 2020 9:51 pm

Debut Biotechnology

SAN DIEGO (PRWEB) January 07, 2020

Debut Biotechnology, a UC-Irvine spinout that is advancing scalable cell-free biomanufacturing, today announced that it has closed a $2.6M seed round from leading venture capital firms and angel investors. The oversubscribed round was led by KdT Ventures, with participation from Better Ventures, FTW Ventures, and SpringTide Ventures.

We invested in Debut because the way we produce therapeutics and high value chemicals will dramatically change in the next 10 years as the pharma industry transitions from complex, multi-step batch manufacturing, to a far more cost-effective and efficient continuous manufacturing system, said Cain McClary, Founder and Managing Partner of KdT Ventures. Debut Bio will be at the forefront of this shift, which we believe represents one of the most promising opportunities in pharma.

Debut Bio helps the pharmaceutical and specialty chemical industries manufacture high-value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. Through the utilization of plug-and-play enzyme cartridges, the companys cell-free platform has the ability to transform low-value bio-renewable materials into high value therapeutics and specialty chemicals.

At our core, we are rethinking industrial biomanufacturing and aiming to produce high value molecules in better ways. Natures enzymes have the ability to create complex natural products, so why reinvent the wheel with chemical synthesis? said Dr. Joshua Britton, CEO and Founder of Debut Biotechnology. Enzyme pathways and evolved proteins hold the key.

Debut Bios enzyme cartridges are sequentially arranged in a manner which mimics pathways found in plants and other organisms. Each cartridge is finely-tuned to provide the ideal temperature, pH, concentration, solvent, and reaction time for each individual step to maximize enzymatic productivity and product titer levels. The platform requires far fewer steps than traditional pharma manufacturing and avoids the use of environmentally harmful chemistry. Importantly, it overcomes many challenges typically associated with relying on cells for biomanufacturing.

Bacteria and yeast have been the workhorses of industrial biomanufacturing for years. Unfortunately, these biofactories have their drawbacks; reaction times can be slow, the product and starting material have difficulty passing through the cell wall, and each cell must be reprogrammed to produce a new molecule, said Dr. Britton. Debut Bio envisions an alternative route.

In Debut Bios system, reactants are passed from one enzyme reactor to another to build in-vitro or cell-free biosynthetic pathways. The companys platform uses a sustainable approach by leveraging advanced enzymes outside of the cell to maximize performance and avoid issues with cell-based systems. The platform technology operates under a continuous manufacturing regime that will provide scale, consistency, and ultimately the ability to produce a biomolecule with the click of a button.

Debut Bio has currently partnered with two large manufacturers to integrate its platform into their existing pipelines. The seed funding will be used to support these integrations, expand business development, double the science team, and create a pilot production system.

Were humbled to have received both support and validation from world class, science-focused investors, said Brady Beauchamp, COO and Co-Founder of Debut Biotechnology. We plan to build on this validation in the coming months with our initial customers in the pharmaceutical manufacturing industry.

This funding comes following an announcement last year that the company spun out of UC Irvine with the exclusive license of two inventions developed by Dr. Joshua Britton and Professor Greg Weiss.

To learn more, please visit: https://debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology is commercializing cell-free biomanufacturing solutions by creating advanced enzyme-based manufacturing processes for high-value molecules. Our platform combines immobilized enzymes with highly controlled and automated continuous manufacturing systems for the pharmaceutical and specialty chemical industries.

Debut Biotechnology was founded by Joshua Britton, Greg Wess, and Brady Beauchamp and is based in sunny San Diego. To learn more, please visit: https://debutbiotech.com/.

Share article on social media or email:

Read more:
Debut Biotechnology Closes $2.6M Seed Round to Bring Continuous Biomanufacturing of High-Value Molecules to Pharma - PR Web

Read More...

Is Therapix Biosciences Ltd – ADR (TRPX) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

January 10th, 2020 9:51 pm

Therapix Biosciences Ltd - ADR (TRPX) is near the bottom in its industry group according to InvestorsObserver. TRPX gets an overall rating of 4. That means it scores higher than 4 percent of stocks. Therapix Biosciences Ltd - ADR gets a 1 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Therapix Biosciences Ltd - ADR (TRPX) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 4 means the stock is more attractive than 4 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Therapix Biosciences Ltd - ADR (TRPX) stock is lower by -6.25% while the S&P 500 is up 0.09% as of 1:52 PM on Friday, Jan 10. TRPX has fallen -$0.06 from the previous closing price of $0.88 on volume of 71,454 shares. Over the past year the S&P 500 is up 26.22% while TRPX has fallen -77.93%. TRPX lost -$2.40 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Therapix Biosciences Ltd - ADR click here.

View post:
Is Therapix Biosciences Ltd - ADR (TRPX) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Read More...

A Preview Of JPMorgan’s Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations – Benzinga

January 10th, 2020 9:51 pm

The 38th annual JPMorgan Healthcare Conference, which is tipped off as the biggest health care investment symposium, kicks off Monday in San Francisco, California.

From the high and mighty to the smallest of nanocaps, biopharma and health care companies have scheduled presentations at the four-day event. It's a no-brainer that the presentations will move stocks and serve as key catalysts for respective companies.

BofA Securities analyst Geoff Meacham expects investors to be acutely focused on 2020 expectations and the potential to maintain the positive momentum of 2019's year-end rally. The analyst is bracing for a conservative tone from larger-cap names, given the moderate but improving growth expectations that would offer scope for multiple guidance revisions throughout the year.

Meacham expects discussions at the conference to be focused on value creating themes such as expanding indications, new product cycles, especially with oncology, inflammation & immunology and orphan diseases and advancing innovation in gene/cell therapy.

"Combined with the unlikelihood of near-term major structural reform and P/E ratios that now lag improving expectations, we remain positive on the sector and the outlook for multiple expansion, with greater generalist participation," Meacham wrote in a note this week.

Here's what BofA expects from some key presenters in its coverage universe.

See also: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Bristol-Myers Squibb Co (NYSE: BMY)

Bristol-Myers Squibb, which completed the acquisition of Celgene late last year, is likely to give at least partial guidance. Meacham believes 2020 guidance could be an early positive driver of shares.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

The analyst expects Vertex to provide fourth-quarter update on its cystic fibrosis agent Trikafta, with the analyst expecting sales of $223 million, well above the consensus estimate of $64 million.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

BioMarin could delve on the commercial opportunity of valrox and vosoritide following the filing for the former and positive Phase 3 data for the latter.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Regeneron is likely to release fourth-quarter sales of Eylea. Given Eylea's declining growth, Meacham said the focus could shift to Dupixent, which remains a key P&L driver.

Biogen Inc (NASDAQ: BIIB)

BofA expects Biogen to specify the timing of its aducanumab regulatory filing, if it hasn't been already submitted. The company could also announce a settlement with Mylan NV (NASDAQ: MYL) over the Tecfidera intellectual property right.

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

Meacham expects Alexion to focus on its portfolio diversification strategy, especially due to pressure from activists and competitors. Updates on ALXN1830 and anti-Factor D ACH-5228 is likely.

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead is likely to update on its global launch plans for filotinib, with the second half of 2020 being the likely timeframe.

Amgen, Inc. (NASDAQ: AMGN)

Meachem expects Amgen to discuss the integration of Otezla into its I&I franchise, update the status of assets in its oncology pipeline and give its expectations for the launch of its biosimilars.

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original post:
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations - Benzinga

Read More...

What to Consider on Vir Biotechnology (VIR) Stock? – News Welcome

January 10th, 2020 9:51 pm

Vir Biotechnology (VIR) registered volume of 79390 shares on Wednesday trading session as compared to an average volume of 206.92K shares. It shows that the shares were traded in the recent trading session and traders shown interest in VIR stock. Listed Shares of the Vir Biotechnology (VIR) moved up 2.05% to trade at $12.43 in the last trading session ended on 01/08/2020. It has a market capitalization of $1.38B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock EPS is $-1.26 against its recent stock value of $12.43 per share.

First we will be looking for the boiling points and excitability of Vir Biotechnology (VIR) stock, it purposes common trait for traders and value investors.

Volatility Indicators for Vir Biotechnology:

Volatility of the Vir Biotechnology remained at 4.22% over last week and shows 5.62% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 0.69.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of -1.15% during the period of last 5 trading days. The stock maintained for the month at -1.51%. The stock noted year to date 2019 performance at -1.15% . The stock is now standing at -24.67% from 52 week-high and is situated at 6.69% above from 52-week low price.

Technical Indicators of Vir Biotechnology Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 45.47.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of VIR is currently down -0.87% from its 20 days moving average and trading -5.32% below the 50 days moving average. The stock price has been seen performing along below drift from its 200 days moving average with -6.63%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Vir Biotechnology:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.

Link:
What to Consider on Vir Biotechnology (VIR) Stock? - News Welcome

Read More...

Is Palatin Technologies, Inc. (PTN) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

January 10th, 2020 9:51 pm

Palatin Technologies, Inc. (PTN) is near the top in its industry group according to InvestorsObserver. PTN gets an overall rating of 49. That means it scores higher than 49 percent of stocks. Palatin Technologies, Inc. gets a 52 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Palatin Technologies, Inc. (PTN) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 49 means the stock is more attractive than 49 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Palatin Technologies, Inc. (PTN) stock is down -7.31% while the S&P 500 has risen 0.09% as of 1:53 PM on Friday, Jan 10. PTN has fallen -$0.05 from the previous closing price of $0.74 on volume of 1,958,045 shares. Over the past year the S&P 500 is up 26.22% while PTN has fallen -8.00%. PTN earned $0.14 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 4.98.

To screen for more stocks like PTN click here.

Read more:
Is Palatin Technologies, Inc. (PTN) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Read More...

Page 733«..1020..732733734735..740750..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick